| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6b47828afb7907039447308a2ae30326
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b03343036c109bee256324d4f4451baf
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a1a03b9d150d5d79db83008c241cd49a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5edd9cfd4a1df197273b07243deb5e91 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H19-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H19-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H21-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H19-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7084
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7072 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H19-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H21-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H19-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H19-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7084
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7072 |
| filingDate |
2009-05-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2d6c6b5f2034fa1349aaae4f1fd9f6c7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_258a5d9ba7e1c0de8144d244e821ab0d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0610fc53dbafa78caf4320dead977400
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_924a07a32e939dfbd1fc41389e160b2f |
| publicationDate |
2009-12-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2009306010-A1 |
| titleOfInvention |
P1-(2'-deoxycytidine 5'-)p4-(uridine 5'-)tetraphosphate, tetra-(alkali metal) salt, for treating disorders |
| abstract |
The present invention provides a method of treating edematous retinal disorders. The method comprises administration of a pharmaceutical formulation comprising a hydrolysis-resistant P2Y receptor agonist to stimulate the removal of pathological extraneous fluid from the subretinal and retinal spaces and thereby reduce the accumulation of said fluid associated with retinal detachment and retinal edema. The P2Y receptor agonist can be administered with therapeutic and adjuvant agents commonly used to treat edematous retinal disorders. The present invention also provides a method of treating cystic fibrosis. The present invention also provides a method of treating sinusitis. The present invention further provides P 1 -(2′-deoxycytidine 5′-)P 4 -(uridine 5′-)tetraphosphate, tetra-(alkali metal) salts such as tetrasodium, tetralithium, tetrapotassium, and mixed (tetra-alkali metal) salts. The present further provides a pharmaceutical formulation comprising a P 1 -(2′-deoxycytidine 5′-)P 4 -(uridine 5′-)tetraphosphate, tetra-(alkali metal) salt, in a pharmaceutically acceptable carrier. |
| priorityDate |
1997-02-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |